Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks by Fensterer, Heiko et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Matrix-comparative genomic hybridization from multicenter 
formalin-fixed paraffin-embedded colorectal cancer tissue blocks
Heiko Fensterer1,12, Bernhard Radlwimmer3, Jörn Sträter2, 
Malte Buchholz1,12, Daniela E Aust4, Catherine Julié6, François Radvanyi7, 
Bernard Nordlinger6, Claudio Belluco8, Eric Van Cutsem9, Claus-
Henning Köhne13, Hans A Kestler1,11, Carsten Schwaenen10, 
Michelle Nessling3, Manfred P Lutz5, Peter Lichter3, Thomas M Gress*1,12 and 
the EORTC Gastrointestinal (GI) Group
Address: 1Department of Internal Medicine I, University of Ulm, Robert-Koch-Strasse 8, 89081 Ulm, Germany, 2Department of Pathology, 
University of Ulm, Robert-Koch-Strasse 8, 89081 Ulm, Germany, 3Division of Molecular Genetics, German Cancer Research Center, Im 
Neuenheimer Feld 280, 69120 Heidelberg, Germany, 4Department of Pathology, University of Technology, Fetscherstraße 74, 01307 Dresden, 
Germany, 5Department of Internal Medicine, Caritasklinik, Rheinstraße 2, 66113 Saarbrücken, Germany, 6Department of Pathology Hôpital 
Ambroise Paré, Boulogne, France, 7UMR144 CNRS – Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, France, 8CRO – IRCCS, National Cancer 
Institute, Via Pedemontana Occidentale, 12, 33081 Avianov(PN), Italy, 9Digestive Oncology Unit, University Hospital Gasthuisberg, 3000 Leuven, 
Belgium, 10Department of Hematology, University of Ulm, Robert-Koch-Strasse 8, 89081 Ulm, Germany, 11Department of Neural Information 
Processing, University of Ulm, 89069 Ulm, Germany, 12Division of Gastroenterology and Endocrinology, Department of Internal Medicine, 
Philipps University, Baldingerstrasse, 35043 Marburg, Germany and 13Division of Oncology and Hematology, Klinikum Oldenburg, Dr.-Eden-
Str.10, 26133 Oldenburg, Germany
Email: Heiko Fensterer - heiko.fensterer@med.uni-marburg.de; Bernhard Radlwimmer - b.radlwimmer@dkfz-heidelberg.de; 
Jörn Sträter - jstraeter@espath.de; Malte Buchholz - malte.buchholz@med.uni-marburg.de; Daniela E Aust - daniela.Aust@pathologie.med.tu-
dresden.de; Catherine Julié - catherine.julie@apr.ap-hop-paris.fr; François Radvanyi - Francois.Radvanyi@curie.fr; 
Bernard Nordlinger - bernard.nordlinger@aps.ap-hop-paris.fr; Claudio Belluco - cbelluco@cro.it; Eric Van 
Cutsem - VanCutsem@uz.kuleuven.ac.be; Claus-Henning Köhne - onkologie@klinikum-oldenburg.de; Hans A Kestler - hans.kestler@uni-
ulm.de; Carsten Schwaenen - carsten.schwaenen@t-online.de; Michelle Nessling - m.nessling@dkfz.de; 
Manfred P Lutz - m.lutz@caritasklinik.de; Peter Lichter - M.MacLeod@dkfz-heidelberg.de; Thomas M Gress* - thomas.gress@med.uni-
marburg.de
* Corresponding author    
Abstract
Background: The identification of genomic signatures of colorectal cancer for risk stratification requires the study of
large series of cancer patients with an extensive clinical follow-up. Multicentric clinical studies represent an ideal source
of well documented archived material for this type of analyses.
Methods: To verify if this material is technically suitable to perform matrix-CGH, we performed a pilot study using
macrodissected 29 formalin-fixed, paraffin-embedded tissue samples collected within the framework of the EORTC-GI/
PETACC-2 trial for colorectal cancer. The scientific aim was to identify prognostic genomic signatures differentiating
locally restricted (UICC stages II-III) from systemically advanced (UICC stage IV) colorectal tumours.
Results: The majority of archived tissue samples collected in the different centers was suitable to perform matrix-CGH.
5/7 advanced tumours displayed 13q-gain and 18q-loss. In locally restricted tumours, only 6/12 tumours showed a gain
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on 13q and 7/12 tumours showed a loss on 18q. Interphase-FISH and high-resolution array-mapping of the gain on 13q
confirmed the validity of the array-data and narrowed the chromosomal interval containing potential oncogenes.
Conclusion: Archival, paraffin-embedded tissue samples collected in multicentric clinical trials are suitable for matrix-
CGH analyses and allow the identification of prognostic signatures and aberrations harbouring potential new oncogenes.
Background
Genomic copy number changes are frequently found in
different types of cancer and are believed to contribute to
their development and progression through inactivation
of tumour suppressor genes, activation of oncogenes, or
more subtle through gene dosage changes. Comparative
genomic hybridization (CGH) [1] was developed to allow
genome-wide screening for such copy number changes.
Conventional CGH has a limited resolution and can
detect losses of 10 Mb or greater [2]. High-level amplifica-
tions achieve a maximum resolution of 3 Mb [3]. The res-
olution of CGH has been improved by replacing the
metaphase chromosomes, which have traditionally served
as hybridization targets, with mapped and sequenced
genomic DNA clones (bacterial artificial chromosomes,
P1-derived artificial chromosome or cosmids) arrayed
onto glass slides which was named "matrix-CGH" [4] or
"array-CGH" [5].
Although genomic DNA arrays are considered powerful
research tools, their potential to meet specific needs in
clinical diagnostics has been debated. Initially, matrix-
CGH was restricted to cell lines or investigated inherited
diseases, both characterized by a genetically homogene-
ous cell population [4,5]. More recently, it was also used
in research studies addressing issues of tumour classifica-
tion and correlation of gene dosage with gene expression
studies [6].
Genomic arrays allow the identification of genomic copy
number alterations that may be suitable for individual-
ized diagnostic, prognostic and therapeutic decision mak-
ing. This is of particular importance since personalized
treatments for cancer patients based on genomic altera-
tions are becoming available. Ideally this type of analysis
is performed using DNA from tumour samples freshly col-
lected and snap frozen in liquid nitrogen. However, this
type of tissue is not always available in clinical routine.
Furthermore, in order to identify prognostic alterations,
the analysis of large numbers of well documented tumour
samples with ample and accurate clinical follow-up data
is required. This information is usually available in con-
trolled multicentric therapeutic studies. Many large-scale
multicentric therapeutic studies such as those from the
EORTC ("European Organisation for Research and Treat-
ment of Cancer") already mandate the collection and stor-
age of formalin-fixed paraffin-embedded tumour samples
in their study protocols [7], and archival paraffin tissue-
blocks can be collected for most patients that participated
in past large multicentric trials which would have the
additional benefit of an extended follow up. Unfortu-
nately, current protocols for matrix-CGH require micro-
gramm quantities of high quality DNA [8]. Such material
can usually not be obtained from the formalin-fixed, par-
affin embedded specimens making these valuable
resources unavailable for the search of prognostic
genomic alterations. Different protocols to overcome this
problem were published [9,10]. Recently, DeVries and
coworkers [10] compared hybridizations with DNA
extracted from formalin-fixed paraffin-embedded breast
cancer tissue samples after manual microdissection and
with DNA derived from the same fresh frozen tumour. In
this study, reproducible results from archived formalin-
fixed paraffin-embbeded tissue samples were obtained
using as little as 50 ng input DNA. However, the condi-
tions available in these studies only partly reflect the situ-
ation found in routine clinical work or in large
multicentric studies. Their tissue blocks were collected by
an expert center and were all derived from one institution,
thus ensuring comparable and high-quality tissue process-
ing. In most clinical trials, tissue blocks will be collected
by a large number of centers, many of them without any
expertise in the processing of samples for molecular anal-
yses and using different protocols for fixation and embed-
ding.
So far it is not known, whether DNA of acceptable quality
for molecular analyses such as matrix-CGH can be
obtained from this type of material in a multicentric set-
ting. In this report, we present a pilot project initiated by
the translational research group of the EORTC-GI group
addressing this particular question. To test the technical
suitability of this type of material, we performed matrix-
CGH analysis of macrodissected colorectal tumours col-
lected in the framework of the EORTC-GI PETACC-2 trial.
In addition to testing the technical feasibility of this
approach, the scientific aim of this pilot project was to
identify prognostic genomic signatures differentiating
locally restricted (UICC stages II-III) from systemically
advanced (UICC stage IV) disease.
Methods
Patients and tumour specimens
29 paraffin-embedded colorectal tumour samples in dif-
ferent stages (10 × UICC II, 11 × UICC III, 8 × UICC IV)
were collected in the framework of the PETACC-2 study.BMC Cancer 2007, 7:58 http://www.biomedcentral.com/1471-2407/7/58
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23 of these samples were from patients which participated
in the trial, and 6 additional samples were generated from
archival material collected by PETACC-2-participants. The
samples were provided by the EORTC-GI group. From one
tumour (no. 29) we did also obtain snap frozen tissue.
The retrospective use of tissue blocks from these patients
for translational research was approved by the ethics com-
mittee of the "Ärztekammer Niedersachsen" (Berliner
Allee 20, 30175 Hannover, Germany, reference number
Grae/128/2002).
Tissue samples were collected at four institutions (Univer-
sity of Padua, Italy, Hôpital Ambroise Paré, Boulogne,
Paris, France, Department of Pathology, University of
Technology, Dresden and Department of Pathology Uni-
versity Hospital of Ulm, Germany). All specimens were
fixed in formalin and paraffin-embedded using the stand-
ard protocols active in the participating centers. Fixation
times were not controlled for and did probably vary. For
diagnostic purposes, paraffin sections of about 3 μm were
performed and stained H&E. For isolation of tumour-spe-
cific DNA, paraffin sections of about 50 μm containing
only tumour tissue after macrodissection of adjacent nor-
mal tissue were collected.
DNA extraction and MSI-testing
DNA extraction of the paraffin embedded tumours was
done using a standard protocol with proteinase K diges-
tion and phenol/chloroform extraction [11], which
yielded between 3 and 15 μg DNA from one section. A
detailed protocol is provided as part of the supplementary
material (additional file 1). In tumour no. 29 DNA was
also extracted from the snap frozen tissue using a standard
protocol [12]. As a control we used DNA from peripheral
leucocytes of healthy volunteers as previously described
[13]. Tumour microsatellite instability status was deter-
mined using the BAT26 microsatellite marker following a
standard protocol [14]. Tumours were defined as having
high-frequency microsatellite instability (MSI-H) if
change of length mutations were detected in BAT26 when
compared with DNA from colon cancer cell lines with
known MSI-status. Because of the quasi monomorphic
nature of the BAT26 polyA tract (size variation is uncom-
mon between germline alleles), this marker can be used to
screen initially for MSI without matching normal DNA
[15].
Array production
Two different types of microarrays were used. DNA from
all tumours was hybridized to a chip previously described
by members of our group [13] containing 644 DNA tar-
gets. For the fine mapping of a selected gain on chromo-
some 13q in one tumour we used an additional chip
containing 6400 DNA targets. These comprise 3200
clones with a genome-wide resolution of 1 MB (Sanger-
Institute, Cambridge, Great Britain) and 2800 additional
clones of regions showing frequent genomic alterations in
cancer or that are known to harbor oncogenes and tumour
suppressor genes. Lists of the clones included in the arrays
together with their genomic localization are provided as
supplementary material (additional files 2 and 3). Clone
preparation and spotting was done as previously
described by our group [6,13].
Array hybridization
Tumour and control DNA (each 250 ng) were labelled
with Cy3 and Cy5-conjugated dCTP by random priming.
Each DNA sample was labeled separately with both fluor-
ophores and used for independent array-hybridizations
("Colour-switch"). Labelled tumour and control DNA
was hybridized to the chip. Detailed protocols are availa-
ble as supplementary material on the journals webpage
(additional file 4).
Data Acquisition and Evaluation
Images of fluorescence signals were acquired by a dual
laser scanner (GenePix 4000 A, Axon Instruments, Foster
City, CA). Assessment of fluorescence signal intensities
was done using GENEPIX PRO 4.0 imaging software. To
identify imbalanced genomic sequences we used a special-
ized algorithm previously developed and validated by our
group [9]. Array experiments were declined for further
analysis if the R value of the Gauss fit did not reach 0.96
(see [9]). In contrast to this protocol, we made no grading
of imbalances: all imbalances were described as gains or
losses, simple gains were not differentiated from amplifi-
cations.
Fluorescence in-situ hybridization (FISH)
Fluorescence in-situ hybridization (FISH) was performed
as previously described for metaphases [16] and inter-
phases [17]. Two-color FISH to 2 μm-sections of the for-
malin-fixed samples was performed with the Rhodamin-
labelled BAC-clones RP11-89P22 (27.7 MB) and RP11-
8C15 (21 MB) with corresponding FITC-labelled BAC-
clone RP11-9F13 (40.7) as a control. To verify their loca-
tion on 13q all these probes were hybridized with leuco-
cytes of healthy volunteers before interphase FISH. The
gain was shown in relation to the control by visual analy-
sis of the hybridization signals. Criteria for gene amplifi-
cation were: tight clusters of signals in multiple cells or at
least three times more test probe signals than control sig-
nals per cell in > 10% of the tumour cells (a minimum of
100 cells were counted).
Results
Quality of DNA extracted from formalin-fixed paraffin-
embedded colorectal cancer samples
A total of 3–15 μg DNA per section suitable for array-
hybridizations could be extracted from 22 tissue blocks,BMC Cancer 2007, 7:58 http://www.biomedcentral.com/1471-2407/7/58
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no DNA or only highly degraded DNA was extractable
from 7 tissue blocks. The clinical characteristics of these
patients are shown in table 1. The quality of the extracted
DNA was checked on agarose gels. Figure 1 shows a repre-
sentative gel with lanes showing no DNA at all (lanes 6
and 9), DNA with a high degree of degradation (lanes 2
and 4 showing the bulk of the DNA between 100 and
1500 bp) and with a moderate degree of degradation
(lanes 3, 5 and 7 bulk of DNA between 400 and 3000 bp).
Best array hybridization results were obtained with DNA
showing a moderate degradation as in lanes 3 (no. 33)
and 7 (no. 39) (Figure 2a), however, interpretable results
could as well be obtained with DNA showing a higher
degree of degradation such as the DNA in lanes 2 (no. 32)
and 4 (no. 36) (Figure 2b). For 3 of the samples, the array
quality was too poor to include them in the further anal-
ysis (the R value of the Gauss fit did not reach 0.96). There
was no correlation of DNA or array quality with the age of
the tumor block.
Stage dependent chromosomal alterations in colorectal 
cancer tumours
For 19 of the initial 29 samples, the DNA quality was good
enough to generate interpretable matrix-CGH-profiles.
Primary tumours already showing clinical evidence of dis-
tant metastasis (UICC stage IV, n = 7) a total number of
13.6 gains or losses per tumour were detected. In contrast,
the UICC stage II (n = 5) and III (n = 7) tumours only dis-
played an average of 10.5 chromosomal imbalances per
tumour (table 2), i.e. 12.4 for stage II and 9.1 for stage III
tumours, respectively. In contrast, taking only into
account chromosomal regions showing gains or losses in
more than 50% of all tumours we saw no significant dif-
ferences in the number of stage dependent chromosomal
aberrations (9.2 for stage II, 9.5 for stage III and 9.7 for
stage IV tumours).
The most frequent imbalances were gains on 20q (14/19),
8q (14/19), 7p (12/19), 13q (11/19), 17q (9/19) and
losses on 1p (12/19), 18q (11/19), 8p (4/19), 17p (4/19).
18q-loss (5/7 UICC IV vs. 7/12 UICC II/III) and 13q-gain
(5/7 UICC IV vs. 6/12 UICC II/III) were more frequently
detected in UICC IV rather than in UICC II/III tumours
(these data are summarized in additional files 5 and 6).
High-resolution mapping of the gain on 13q using 
interphase FISH and high-density genomic arrays
In the original hybridization approach using the 644-fea-
ture array, the gain on 13q was one of the most frequent
alterations in UICC IV tumours and included the large
region between the BAC clones RP11-8C15 (21 Mb) and
RP11-89P22 (27.7 Mb) as minimally involved area in all
samples. Because the time this study was performed, this
region was the least well known, we decided to confirm
the validity of this array-CGH data by interphase FISH and
to further characterize it. The gain in one of the tumours
(no. 29) used for the initial screen with the low density
arrays precisely displayed the minimally involved area
from 21–27.7 Mb. The consecutive clone on this low den-
sity array located at 40.7 Mb (RP11-9F13) appeared not to
be involved (Figure 4a). Interphase FISH using the 3
clones described above was done with histological sec-
tions of this particular tumour sample (Figure 3). It
showed the typical pattern of a high level amplification
for the clones RP11-8C15 and RP11-89P22, whereas the
apparently not involved clone RP11-9F13 was confirmed
to be localized outside of the amplified area.
To identify the smallest possible area of amplification and
to narrow down the number of potential candidate dis-
ease genes, we repeated the matrix-CGH of this tumour
sample using a higher resolution 6400-clone-chip and
DNA from snap frozen tissue (Figure 4). Although it was
possible to pinpoint the distal border of this gain to the
area between 30.01 (BAC-clone RP11-550P23) and 30.67
Mb (RP11-173P16), the gain involved all proximal BAC
clones available on this high density array up to 18.50 Mb
(RP11-408E5). Thus, the aim to narrow down the mini-
mal area harboring the disease gene was only partially
achieved.
Discussion
The presented data demonstrates that it is possible to
extract DNA of sufficient quality to perform matrix-CGH
from the majority of archival formalin-fixed, paraffin-
embedded tumour samples collected at different institu-
tions. This reflects the situation encountered in most mul-
ticentric therapeutic clinical trials where ample clinical
and follow-up data is available, but tissue samples are
either not collected systematically or at least not using a
standardized protocol for tissue processing, fixation and
embedding. In this study, 66% (19/29) of the tissue
blocks, irrespective of the institutional origin or the age of
the blocks, delivered DNA suitable for array hybridiza-
tions employing a simplified method for tumour cell
enrichment involving a minimal number of tissue han-
dling steps. The procedure of paraffin embedding and the
fixation time have been shown to be able to influence the
DNA quality. However, these factors could not be evalu-
ated retrospectively. Further improvements in data quality
can be realized with snap frozen samples or with paraffin-
embedded tissue, once procedures for tissue processing
have been standardized to ensure optimal conditions for
molecular analyses and are routinely used in multicentric
therapeutic trials to collect tissue. Such an approach is
increasingly used by the EORTC-GI group for the
PETACC-trials of adjuvant treatment for colorectal cancer
patients, and among others the present study was done to
verify and optimize tissue sampling protocols for genomic
analyses (for example PETACC-4). Our study indicatesBMC Cancer 2007, 7:58 http://www.biomedcentral.com/1471-2407/7/58
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that it should be technically feasible for the time being to
use the large collections of formalin-fixed paraffin embed-
ded tumour tissues for genomic analyses collected by the
local pathologists during the routine workup of resected
tumour samples of patients included in closed multicen-
tric therapeutic trials. This possibility opens the road for
systematic analyses of these archival materials with an
excellent long-term follow-up to identify prognostic
genomic signatures e.g. by the use of matrix-CGH imme-
diately without the need to wait for the follow up of ongo-
ing prospective studies.
Analysis of the array hybridizations revealed consistent
regions of copy number changes. Many of the findings
were in agreement with those observed previously in con-
ventional CGH [18]and matrix-CGH [19-21]. investiga-
tions, thus confirming the validity of our hybridizations
with DNA extracted from archival formalin-fixed, paraf-
fin-embedded tumour tissue collected at multiple centers.
This includes the most frequent gains observed in our
study over all different tumour stages such as 20q, 8q, 7p,
13q, and 17q, as well as the most frequent losses on 1p,
18q, 8p and 17p.
Since the list of candidate genes involved in these altera-
tions is very large and has been discussed elsewhere [19-
21], we will not elaborate in a detailed discussion of indi-
vidual candidates. The scientific goal of this pilot matrix-
CGH study was to identify genomic signatures associated
with systemically advanced colorectal tumours. Since only
15% of UICC III patients will benefit from the routinely
administered systemic adjuvant chemotherapy [22],
genomic signatures could serve to select patients with a
high risk of recurrence who would have the major benefit
from an adjuvant treatment.
Genomic profiles from primary tumours of patients with
clinical evidence of metastases (UICC stage IV) differed
from those of locally restricted tumours (UICC II/III) only
by the type of chromosomal imbalances. The average total
number of gains and losses per tumour were not different
between different tumour stages, which is in agreement
with a recent study of Dukes C colorectal tumours using
conventional CGH. In this study, Rooney and coworkers
found that the number of aberrations was highly variable.
21% of the tumours showed no aberration, whereas 41%
displayed 1–8 and 38% 11–20 aberrations [23]. Interest-
Table 1: Patient characteristics of the 29 patients in which DNA extraction was performed ("+" = good quality, "-" = bad quality, n.d. = 
not done, F = female, M = male, n.k. = not known, n.a. = not available)
Code DNA 
quality
Interpretable 
profile
Age Sex Site G T N M UICC 
Stage
Date of sample 
preparation
MSI 
status
1 + no 72 F left colon 2 2 x 1 4 06/01 n.d.
2 + no 67 M left colon 2 3 1 1 4 03/00 neg.
3 + yes 63 M right colon 2 3 2 0 3 05/98 n.d.
4 + yes 75 F right colon 2 2 2 1 4 10/00 n.d.
5 + yes 78 M left colon 2 3 1 0 3 03/95 neg.
6 + yes 80 M rectum 2 3 0 0 2 03./99 n.d.
7 + yes 75 M left colon 2 2 1 0 3 02/98 n.d.
8 - n.d. 65 F left colon 2 2 2 0 3 04/99 n.d.
9 + yes 60 M rectum 2 3 1 0 3 01/99 neg.
10 - n.d. 65 M right colon 2 3 0 0 2 02/00 n.d.
11 + yes 43 M rectum 2 3 1 0 3 12/98 n.d.
13 - n.d. 64 M coecum 3 3 1 0 3 10/97 n.d.
15 + yes 66 F rectum 2 3 0 0 2 01/92 n.d.
17 + no 58 F left colon 2 2 1 0 3 07/94 n.d.
18 + yes 51 M left colon 2 3 0 0 2 11/97 neg.
19 + yes 57 M left colon 2 3 1 0 3 07/92 neg.
21 neg. n.d. 53 F rectum 2 3 0 0 2 10/97 n.d.
22 neg. n.d. 40 F left colon 2 4 1 0 3 05/98 n.d.
23 + yes 64 F left colon 1 3 0 0 2 11/92 neg.
25 + yes 62 F right colon 2 3 1 1 4 10/01 neg.
26 neg. n.d. 67 F left colon 3 3 0 0 3 12/99 n.d.
27 + yes 60 M right colon 2 3 0 0 2 n.a. neg.
29 + yes 67 M left colon 2 3 1 1 4 05./99 neg.
32 + yes 57 F right colon 3 3 1 1 4 01/02 n.d.
33 + yes 72 M left colon 3 3 1 1 4 03./02 neg.
36 + yes 60 M rectum 3 3 1 0 3 n.k./01 neg.
37 + yes 76 F right colon 2 3 0 0 2 06/96 neg.
38 neg. n.d. 76 F left colon 2 3 1 0 3 08/97 n.d.
39 + yes 63 M rectum 2 3 2 1 4 11/01 neg.BMC Cancer 2007, 7:58 http://www.biomedcentral.com/1471-2407/7/58
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ingly, in their study patients with more than 2 aberrations
appeared to have a better survival than patients with fewer
regions of losses and gains.
In contrast, we found a number of imbalances that were
more frequent in the UICC IV tumours. The most frequent
imbalances were loss on 18q (100% UICC IV vs. 58.3%
UICC II/III) and gain on 13q (85.7% UICC IV vs. 58.3%
UICC II/III). Loss on 18q included the well known
18q21.1 area which is known to harbour the tumour sup-
pressor genes SMAD2 [24] and SMAD4 [25], which func-
tion in the TGFβ-pathway e.g. to mediate the growth-
inhibitory effects of this cytokine. Allelic loss at 18q21.1
and mutations of SMAD4  are common alterations in
colorectal cancer [26]. Loss of 18q has as well been found
in the recently published array-CGH analyses of colorectal
cancer [19-21], though an association to more advanced
stages has not yet been reported in these studies. LOH-
analyses have shown that 18q allelic loss is a strong pre-
dictive factor [27]. Moreover, Dukes C tumours with
SMAD4 expression show a significantly longer disease-
free survival [28] and significantly more benefit from 5-
fluorouracil-based chemotherapy [29].
Since at the time when we started this study little detail
was available concerning the 13q gain, we decided to fur-
ther characterize this alteration by high-resolution map-
ping using high-density genomic arrays and interphase
FISH-analyses. Interphase FISH showed the typical pat-
tern of a high-level chromosomal amplification. After fin-
ishing the experimental part of the project, a number of
manuscripts were published describing genomic profiles
of colorectal tumours obtained with matrix-CGH [19], all
confirming the high incidence of 13q gains. However, the
area described in these studies was very large and was cov-
ered by more than 20 BAC clones in most studies [20,21].
Our high resolution mapping allowed us to define the dis-
tal border of this gain to the area between 30.01 and 30.67
Mb. However, the aberration involved all proximal BAC
clones available on the high density array, thus still leav-
ing a chromosomal area of at least 11.51–11.17 Mb
(between 18.50 MB and 30.01–30.67) as minimally
amplified region. This area includes numerous candidate
oncogenes such as FLT3, a tyrosine kinase receptor in
which activating mutations have been found in acute
myeloid leukemia [30], FLT1, a vascular endothelial
growth factor receptor found to be expressed in gastric and
breast carcinoma cells [31], and FGF9. FGF9 is a potent
mitogen that stimulates normal and cancer cell prolifera-
tion [32] and appears to be involved in the pathogenesis
of a number of tumours such as prostate cancer [33],
Comparison of different DNA samples after extraction Figure 1
Comparison of different DNA samples after extraction: Lane 1: DNA-ladder, 2–7 and 9: DNA from paraffin-embedded color-
ectal cancer samples, lane 8: no DNA loaded, lane 10+11: DNA from cultured cells.
11 0 5
500 
bp
32 33 36 37 38 39 10
lane
tumor 1BMC Cancer 2007, 7:58 http://www.biomedcentral.com/1471-2407/7/58
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melanomas [34], brain tumours [35], and breast cancer
[36].
Conclusion
In conclusion, the presented study shows that it is feasible
to perform high-throughput analyses of genomic profiles
of colorectal tumours using archival formalin-fixed, paraf-
fin-embedded tissue samples, such as those collected by
institutional pathologists from patients participating in
multicentric clinical trials. The results obtained for the
gain on 13q show that relevant data can be obtained using
this setting, which is as well confirmed by the fact that the
results obtained in this study are comparable to published
genomic profiles obtained with ideal material such as
snap frozen tissue. The amplification on 13q appears to
harbour candidate genes that may confer a more aggres-
sive phenotype to colorectal cancer cells. Further studies
with larger series of patients are warranted to identify the
relevant oncogene.
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Representative figures of two-colour FISH on 2 μm-sections of a formalin-fixed tumour sample from no. 29 was performed  with the Rhodamin-labeled BAC-clones RP11-89P22 (figure 3a) and RP11-8C15 (figure 3b) and compared with the FITC- labeled BAC-clone RP11-9F13 used as control in figure 3a and 3b Figure 3
Representative figures of two-colour FISH on 2 μm-sections of a formalin-fixed tumour sample from no. 29 was performed 
with the Rhodamin-labeled BAC-clones RP11-89P22 (figure 3a) and RP11-8C15 (figure 3b) and compared with the FITC-
labeled BAC-clone RP11-9F13 used as control in figure 3a and 3b. The Rhodamin-labeled signal appears in red and the FITC 
labeled signal in green (original magnification 630×). It showed the typical pattern of a high level amplification for the clones 
RP11-8C15 and RP11-89P22, whereas the apparently not involved clone RP11-9F13 was confirmed to be localized outside of 
the amplified area.
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High resolution-mapping of the gain on 13q in tumour 29 using the 6 k array (figure 4b) as compared to the profile obtained  with the 0.64 k genomic array (figure 4a) Figure 4
High resolution-mapping of the gain on 13q in tumour 29 using the 6 k array (figure 4b) as compared to the profile obtained 
with the 0.64 k genomic array (figure 4a). Log2 ratios for the different BAC clones (y-axis) are displayed according to their 
chromosomal position (x-axis).
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